AI In Pathology Market Summary
The global AI in pathology market size was estimated at USD 134.57 million in 2024 and is projected to reach USD 1,151.55 million by 2033, growing at a CAGR of 27.18% from 2025 to 2033. Growing demand for precision medicine, rising prevalence of chronic diseases, technological advancements are significant factors contributing to market growth.
Key Market Trends & Insights
- North America AI in pathology market accounted for the largest revenue share of 40.47% in 2024.
- The U.S. AI in pathology market held the largest market share in 2024.
- Based on component, software segment held the largest market share of 51.27% in 2024.
- Based on technology, the machine learning segment accounted for the largest revenue share of 35.75% in 2024.
- Based on application, the image analysis segment accounted for the largest revenue share of 36.44% in 2024.
Market Size & Forecast
- 2024 Market Size: USD 134.57 Million
- 2033 Projected Market Size: USD 1,151.55 Million
- CAGR (2025-2033): 27.18%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Moreover, the growing digitization of pathological infrastructure, supportive regulatory progress, and industry partnerships are strengthening the market environment. The growing demand for precision medicine is one of the significant drivers of AI in pathology market. AI facilitates tailored treatments by integrating histopathological image analysis with genomic data to provide more precise disease subtyping and prognosis. For instance, in July 2025, LG AI Research unveiled its upgraded pathology AI model, EXAONE Path 2.0, to enhance cancer diagnosis and drug development. The system combines analysis of both entire slide images and smaller patches to avoid feature collapse and preserve contextual information. Trained on multi-omics data, including DNA, RNA, and whole slide pathology images, the model analyzes genetic mutations, gene expression, and subtle tissue changes with 78.4% prediction accuracy.
In addition, growing funding for AI research and healthcare digital transformation programs, alongside rising adoption of telepathology, support the deployment of AI tools on a large scale. For instance, in March 2025, Proscia secured USD 50 million in funding to accelerate the adoption of its AI-powered Concentriq platform, an AI-driven pathology solution, to integrate more AI capabilities and leverage partnerships with OEMs like Agilent Technologies and Siemens Healthineers.
Workflow optimization and operational efficiency in laboratories also significantly fuel the adoption of AI pathology solutions. AI-driven automation of routine tasks such as tissue segmentation, cell counting, and measurement reduces manual labor and human error, allowing pathologists to devote more time to complex cases. For instance, in January 2025, Owkin unveiled new insights into digital pathology and AI solutions, highlighting challenges such as rising pathologist burnout due to workload and diagnostic complexity. Their AI diagnostics support quick interpretation of whole slide images, biomarker screening, and patient outcome predictions to enable precision oncology.
Furthermore, industry partnerships are strengthening the market environment. Pharmaceutical companies are collaborating with AI developers to incorporate digital pathology into clinical trials and drug development. For instance, in April 2025, Precision for Medicine and PathAI announced a strategic collaboration to develop novel AI technologies and integrate PathAI’s advanced digital pathology capabilities into Precision for Medicine’s clinical trial and biospecimen operations. Precision for Medicine is expected to leverage PathAI’s AISight image management system and AI algorithms to enhance biospecimen analysis workflows with quality control steps, improving data consistency and reliability.
Recent Developments in the AI In Pathology Market
| -Kristie Dolan, Senior Vice President, Oncology, Quest Diagnostics. |